In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Jessica Mcalpine and Amy Jamieson to discuss p53abn and no myoinvasion endometrial cancer. Dr. Jessica McAlpine is a surgeon-scientist at the University of British Columbia and BC Cancer and a Tier 1 Canada Research Chair. Dr. Amy Jamieson is a gynecologic oncologist at Vancouver General Hospital and BC Cancer and an Assistant Professor at the University of British Columbia.   Highlights: • p53abn endometrial cancers are aggressive tumours, responsible for the majority of recurrences and death from th ..read more

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Giorgio Bogani to discuss Mirvetuximab in Ovarian Cancer. Prof. Bogani serves as a consultant in gynecologic oncology at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano in Milan, Italy. He completed a research fellowship at the Mayo Clinic in Rochester, MN, USA, with a focus on endometrial cancer and gynecologic oncology. Currently, his expertise is centered on gynecological surgery and experimental medicine.   Highlights: Mirvetuximab soravtansine-gynx is a ADC comprising a FRα-dir ..read more

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Andrea Rosati. Mr. Rosati is a consultant at the Department of Gynecologic Oncology at Fondazione Policlinico Universitario Agostino Gemelli in Rome (Italy). He is currently attending a second level master "Gynecologic Oncology International Master" at the Catholic University of the Sacred Heart (Rome, Italy) accredited as a Subspecialty Fellowship by the European Society of Gynaecological Oncology. His main interest areas are gynecological cancer, surgical anatomy, and gynecologic oncology surgery.   ..read more

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Maaike Oonk to discuss the ESGO Vulvar Cancer Guidelines for 2023. Dr. Oonk is a gynaecological oncologist in the University Medical Center Groningen in the Netherlands. Her research focuses on new treatment options for vulvar cancer patients to improve quality of life. She is PI of the GROINSS-V studies and was chair of the 2023 ESGO vulvar cancer guidelines working group.   Highlights: Inguinofemoral radiotherapy is a safe alternative for a lymphadenectomy in patients with micrometastasis in the sen ..read more

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Mr. Hani Marcus to discuss the IDEAL Framework. Mr. Marcus is a Consultant Neurosurgeon at the National Hospital for Neurology and Neurosurgery and Honorary Associate Professor at the UCL Queen Square Institute of Neurology.   Highlights: - The development of the next generation of surgical robotics presents unique challenges in evaluation due to their complexity, integration with AI, and potential for system disruption. - The IDEAL (Idea, Development, Exploration, Assessment, and Long-term monitoring) Rob ..read more

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Christina Fotopoulou, Ane Gerda Z. Eriksson, Glauco Baiocchi, and Oliver Zivanovic to discuss the 2024 Special Issue of IJGC, “Novel Surgical Approaches in Gynecological Oncology”. Dr. Fotopoulou is the Chair of Gynaecological Cancer Surgery at the Department of Surgery and Cancer at Imperial College London, UK. She has served as an elected ESGO council member and Chair of the ESGO and BGCS guidelines committee. Dr. Eriksson is the chair of the endometrial cancer and gyn sarcoma group at the Department of ..read more

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Mary McCormack to discuss the INTERLACE trial. Dr. McCormack is an Honorary Consultant Clinical Oncologist at University College London Hospitals NHS Trust and an Honorary Associate Clinical Professor at University College London.   Highlights: • INTERLACE first randomised PH3 trial in Locally advanced cervical cancer in more than 2 decades to demonstrate a clinically meaningful and statistically significant improvement in both OS and PFS . • The IC drugs are widely available and relatively cheap so re ..read more

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Em. Ignace Vergote to discuss innovaTV205. Prof. Vergote was Chairman of the Department of Gynaecology and Obstetrics at the Catholic University Leuven from 2003-2020. He published more than 1050 papers on gynecologic cancer in peer-reviewed journals, and his work was cited more than 90,000 times. He served as President of IGCS, ESGO, EORTC-GCG and ENGOT.   Highlights: Tissue factor is almost always highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody ..read more

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Gabriella Schivardi to discuss trends and complications after the LACC Trial. Dr. Schivardi is a first year ESGO fellow at the European Institute of Oncology in Milan and a research collaborator at the Gynecologic Oncology Department at Mayo Clinic, Rochester, United States. In addition, she is a former fellow for the IJGC.   Highlights: The study observed a significant decrease in the use of the minimally invasive approach after the publication of the LACC trial. Within our population the 30-day ..read more

In this episode of the IJGC Podcast, Editorial Fellow Sabrina Piedimonte and Ilaria Capasso discuss the contents of the February issue of IJGC ..read more